Author

E. Mahe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Laurent· 1 shared A. Verge de los Aires· 1 shared B. P. Fairfax· 1 shared C. A. Taylor· 1 shared C. Le Peron· 1 shared G. Palierne· 1 shared G. Salbert· 1 shared H. Ruffieux· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Laurent

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis

A. Laurent, T. Madigou, M. Bizot, M. Turpin, G. Palierne, E. Mahe, S. Guimard, R. Metivier, S. Avner, C. Le Peron, G. Salbert

This study shows that TET2-mediated epigenetic changes in breast cancer cells reduce tumorigenic potential by altering gene expression related to lysosome biogenesis and MYC regulation.

bioRxiv · Oct 27, 2021Cancer Biology

Sensitivity to Immune Checkpoint Blockade and Progression-Free Survival is associated with baseline CD8+ T cell clone size and cytotoxicity

R. A. Watson, O. Tong, R. A. Cooper, C. A. Taylor, P. K. Sharma, A. Verge de los Aires, E. Mahe, H. Ruffieux, I. Nassiri, M. R. Middleton, B. P. Fairfax

The paper uses single-cell and bulk RNA sequencing to show that CD8+ T cell subset and clone size influence gene expression responses to immune checkpoint blockade, and that pre-treatment cytotoxicity and clonality predict progression-free survival.

bioRxiv · Nov 15, 2020 · PreprintImmunology